ResMed Posts Record Revenue but Faces Margin Pressures
Event summary
- ResMed reported Q4 revenue of $1.5 billion, up 9% year-over-year.
- Full-year 2026 revenue reached $5.7 billion, with a 10% increase.
- Non-GAAP diluted earnings per share rose 16% to $2.95 in Q4.
- The company returned $1 billion to shareholders through repurchases and dividends.
- ResMed announced plans to sell its MatrixCare business.
The big picture
ResMed's strong financial performance reflects sustained demand for its sleep and respiratory health products. However, the sale of MatrixCare and integration of Noctrix Health highlight a strategic pivot that could reshape its long-term growth trajectory. The company's ability to balance innovation with profitability will be critical in an increasingly competitive healthcare technology landscape.
What we're watching
- Strategic Realignment
- The sale of MatrixCare signals a potential shift in ResMed's focus away from residential care software.
- Execution Risk
- ResMed must demonstrate sustained demand for its sleep devices and masks amid competitive pressures.
- Financial Discipline
- The company's ability to maintain gross margin expansion while investing in innovation will be key.
Related topics